Persistence of high-grade cervical dysplasia and cervical cancer requires the continuous expression of the human papillomavirus type 16 E7 oncogene.
about
Dysregulation of Autophagy Contributes to Anal CarcinogenesisMechanistic insights into ADXS11-001 human papillomavirus-associated cancer immunotherapy.Alternative splicing of human papillomavirus type-16 E6/E6* early mRNA is coupled to EGF signaling via Erk1/2 activation.Immunotherapy for cervical cancer: Research status and clinical potentialEstrogen and ERalpha: culprits in cervical cancer?Rapamycin inhibits anal carcinogenesis in two preclinical animal models.APOBEC3A functions as a restriction factor of human papillomavirusPrimary human cervical carcinoma cells require human papillomavirus E6 and E7 expression for ongoing proliferation.Lm-LLO-Based Immunotherapies and HPV-Associated DiseaseThe Human Papillomavirus E6 PDZ Binding Motif: From Life Cycle to Malignancy.Cervical cancers require the continuous expression of the human papillomavirus type 16 E7 oncoprotein even in the presence of the viral E6 oncoproteinBioluminescent imaging of HPV-positive oral tumor growth and its response to image-guided radiotherapyIlluminating cancer systems with genetically engineered mouse models and coupled luciferase reporters in vivoLoss of Dependence on Continued Expression of the Human Papillomavirus 16 E7 Oncogene in Cervical Cancers and Precancerous Lesions Arising in Fanconi Anemia Pathway-Deficient Mice.Suppression of Antitumor Immune Responses by Human Papillomavirus through Epigenetic Downregulation of CXCL14.The papillomavirus E7 proteins.Prevention and treatment of cervical cancer in mice using estrogen receptor antagonists.Requirement of estrogen receptor alpha DNA-binding domain for HPV oncogene-induced cervical carcinogenesis in mice.Gene expression profile regulated by the HPV16 E7 oncoprotein and estradiol in cervical tissueMicroRNAs and their role in gynecological tumors.The HPV16 oncogenes cause aberrant stem cell mobilization.Association of human papillomavirus with Fanconi anemia promotes carcinogenesis in Fanconi anemia patients.Immunotherapy and targeted therapy for cervical cancer: an update.DNA-based immunotherapy for HPV-associated head and neck cancer.The human papillomavirus E7 oncoprotein as a regulator of transcription.miR-135a leads to cervical cancer cell transformation through regulation of β-catenin via a SIAH1-dependent ubiquitin proteosomal pathway.Imaging to study solid tumour origin and progression: lessons from research and clinical oncology.HPV16 E7 Genetic Conservation Is Critical to Carcinogenesis.Human Papillomavirus 16 E7 Stabilizes APOBEC3A Protein by Inhibiting Cullin 2-dependent Protein Degradation.Integration of oncogenes via Sleeping Beauty as a mouse model of HPV16+ Oral tumor and immunologic control.DNA Tumor Virus Regulation of Host DNA Methylation and Its Implications for Immune Evasion and Oncogenesis.Dek overexpression in murine epithelia increases overt esophageal squamous cell carcinoma incidence.Terc is dispensable for most of the short-term HPV16 oncogene-mediated phenotypes in mice.Nuclear lactate dehydrogenase A senses ROS to produce α-hydroxybutyrate for HPV-induced cervical tumor growth
P2860
Q28554496-495F5771-23E1-418E-A569-A5542CD01B1BQ33755840-99280FF1-9C54-494E-B457-D384E4C105C1Q33859710-8D94C066-2A2C-4702-95F3-77038A6C97A5Q34033763-35D4BDE0-53AD-4709-86CC-8A82F8336E47Q34037344-6E5FE303-786C-45BE-BD2E-3F267FF7CCE3Q34679829-93ECCA13-9E8A-4C74-83F9-F28375CCBC2DQ34992751-1A21D246-7E09-4058-9041-29F931E0EA56Q35589596-DD6F931A-48B2-4FD8-AF6F-A42B704DE51BQ35838127-1611E736-A7B3-4237-93E5-20E08B21597EQ35895297-9C4B4179-6388-4090-A20B-13E25F9EAA45Q36170110-3BB5F322-6350-4AD2-9003-7F7982EE7F47Q36326544-98F538D8-C0DC-4A88-82E6-D0684E283A9FQ36920226-9D05D38C-1C97-4277-84BA-7EABEB968A78Q36974213-C8A38DBA-688A-4C0B-8196-8D7E0E9BC8DFQ37123428-0AE0745B-17F8-4CBE-909F-4D87B857FAA1Q37198662-EA87466F-D3F2-461D-81FB-2D0A63C9C293Q37428887-3383C602-E155-478D-90BC-3E775D8FD6E4Q37537557-DE552E82-0F6D-4814-8C88-CBE1039C009CQ37696662-596E73A6-764D-4AF2-8387-E6333BF6ADE7Q37722649-AAC16D25-EC50-4F28-B18D-68FA034D3161Q38275216-1DCFB4CA-B28C-4239-9F68-A20875D1C37CQ38380216-F21D79CC-3066-4061-B162-A00B4330E3E0Q38633525-09BAC896-B247-440E-9941-7C4D36513A05Q38948889-FA3F3523-00BE-43D6-B502-312353EBFD58Q39000409-D304922F-BB22-42C4-911A-3FA407F736A8Q39026464-FA67C002-B8D7-4D70-AE5B-DCEFEE43B1A8Q39178993-1EAE681A-3DA2-4DE4-A158-5DABD0E22DD4Q40050669-83121727-82BB-432B-A5F2-CC9A94223A16Q47549187-72E8F777-3011-482A-9385-BAFA367B13D0Q47549568-37AE4686-FD84-4F5E-AC82-C0966FD19798Q50042001-F442B047-2398-49D1-8F57-9AD60168376CQ52656023-9A78F08A-9D97-4780-A830-D2CA80FD851AQ55333841-378EAE1E-9291-4AB2-88A9-2D69BC3AE204Q57793552-89DA456E-041F-4B18-AC5E-0900F54EB606
P2860
Persistence of high-grade cervical dysplasia and cervical cancer requires the continuous expression of the human papillomavirus type 16 E7 oncogene.
description
2009 nî lūn-bûn
@nan
2009 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Persistence of high-grade cerv ...... lomavirus type 16 E7 oncogene.
@ast
Persistence of high-grade cerv ...... lomavirus type 16 E7 oncogene.
@en
Persistence of high-grade cerv ...... lomavirus type 16 E7 oncogene.
@nl
type
label
Persistence of high-grade cerv ...... lomavirus type 16 E7 oncogene.
@ast
Persistence of high-grade cerv ...... lomavirus type 16 E7 oncogene.
@en
Persistence of high-grade cerv ...... lomavirus type 16 E7 oncogene.
@nl
prefLabel
Persistence of high-grade cerv ...... lomavirus type 16 E7 oncogene.
@ast
Persistence of high-grade cerv ...... lomavirus type 16 E7 oncogene.
@en
Persistence of high-grade cerv ...... lomavirus type 16 E7 oncogene.
@nl
P2093
P2860
P1433
P1476
Persistence of high-grade cerv ...... lomavirus type 16 E7 oncogene.
@en
P2093
Adam Glick
Linda Abrams
Paul F Lambert
Sean F Jabbar
P2860
P304
P356
10.1158/0008-5472.CAN-09-0023
P407
P577
2009-05-12T00:00:00Z